Stay updated on Nivolumab Plus Ipilimumab Neoadjuvant Therapy Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab Neoadjuvant Therapy Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab Neoadjuvant Therapy Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedPublication added under Publications: Lancet Oncology 2024 article on pathological response following neoadjuvant immune checkpoint inhibitors in hepatocellular carcinoma (HCC).SummaryDifference0.1%

- Check30 days agoChange DetectedAdded Hepatocellular carcinoma as a condition term and a Genetics and Rare Diseases Information Center resource. The site footer revision updated from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check45 days agoChange DetectedFooter revision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check66 days agoChange DetectedThe only visible change is the page revision label updated from Revision: v3.4.1 to Revision: v3.4.2, with no observed changes to study details or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check73 days agoChange DetectedPublications section updated: added a new long-term efficacy and biomarker exploration paper (J Hepatol. 2026) and revised the citation to v3.4.1; removed the 2025 online-ahead-of-print reference. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Plus Ipilimumab Neoadjuvant Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab Neoadjuvant Therapy Clinical Trial page.